安进公司

AMGN represents Amgen Inc., a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. Its products address areas such as oncology, inflammation, cardiovascular disease, bone health, and nephrology. The company also operates a manufacturing network and conducts extensive research and development. Amgen sells its medicines in the United States and internationally, generating revenue primarily from product sales. Investors often track its pipeline and key product performance when evaluating AMGN.

Recent performance for AMGN can be found in the price and performance section of this page, which shows the latest available data, including price changes over various periods. Stock performance reflects company-specific news, sector trends, and broader market conditions. For the most current returns, compare the displayed performance figures with relevant benchmarks. No single period should be viewed in isolation when assessing AMGN.

Evaluating AMGN’s valuation typically involves comparing metrics such as the price-to-earnings ratio, price-to-sales ratio, and enterprise value to EBITDA against peers in the biotechnology sector. Analysts also consider growth prospects, pipeline strength, and profitability. The latest valuation multiples for AMGN are shown on this page. It is helpful to review these alongside historical ranges and industry averages, since valuation can vary with market sentiment and financial results.

AMGN can be traded during regular U.S. market hours, typically 9:30 a.m. to 4:00 p.m. Eastern Time on weekdays, excluding market holidays. Many brokers also offer pre-market and after-hours trading sessions, though liquidity and price volatility may differ from the regular session. The exact hours and available sessions depend on your brokerage. For current trading status, refer to the market data displayed on this page.

Analyzing AMGN’s financial performance involves reviewing its income statement, balance sheet, and cash flow statement. Key metrics include revenue growth, net income, earnings per share, operating margin, and free cash flow. Comparing these figures across quarters and against industry peers can reveal trends in profitability and efficiency. AMGN’s reported financial results are available in its quarterly and annual filings, and summarized financial data may also appear on this page.

Risks for AMGN include clinical trial failures, regulatory delays or rejections, patent expirations, and pricing pressure from insurers or government policies. Competition from biosimilars and other therapies can reduce market share. Macroeconomic factors, such as interest rates and currency fluctuations, may affect financial results and stock price. Additionally, reliance on key products means that any setback to those products could disproportionately impact AMGN. Investors often monitor these risks through company filings and news updates.